0000000000601642

AUTHOR

Elke Pogge Von Strandmann

showing 2 related works from this author

Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicl…

2018

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines fo…

ectosomeectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardization; Histology; Cell Biology[SDV]Life Sciences [q-bio]minimal information requirementsectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardizationsize-exclusionectosomesMedicine and Health SciencesCELL-DERIVED MICROPARTICLESFIELD-FLOW FRACTIONATIONguidelinesrequirementscirculatingComputingMilieux_MISCELLANEOUSmicroparticlesManchester Cancer Research Centrelcsh:Cytologyextracellular vesicles; exosomes; ectosomes; microvesicles; minimal information requirements; guidelines; standardization; microparticles; rigor; reproducibilityPROSTATE-CANCERmicroparticleCell interactionmicrovesiclechromatographyPosition Paperextracellular vesiclesguidelineLife Sciences & Biomedicinemicrovesiclesectosomes exosomes extracellular vesicles guidelines microparticles microvesicles minimal information requirements reproducibility rigor standardizationMEMBRANE-VESICLESHistologyFETAL BOVINEEctosomes ; Exosomes ; Extracellular Vesicles ; Guidelines ; Microparticles ; Microvesicles ; Minimal Information Requirements ; Reproducibility ; Rigor ; StandardizationCIRCULATING MICROPARTICLES[SDV.BC]Life Sciences [q-bio]/Cellular Biologyexosomesddc:570exosomeSURFACE-PLASMON RESONANCEddc:610lcsh:QH573-671BiologyreproducibilitystandardizationInteracció cel·lularScience & TechnologyResearchInstitutes_Networks_Beacons/mcrcCell BiologyrigorCell membranesHUMAN URINARY EXOSOMESPREANALYTICAL PARAMETERSminimal information requirementSIZE-EXCLUSION CHROMATOGRAPHY1182 Biochemistry cell and molecular biologyextracellular vesicleHuman medicineMembranes cel·lulars
researchProduct

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

2016

International audience; Despite effective targeted therapy acting on KIT and PDGFRA tyrosine kinases, gastrointestinal stromal tumors (GIST) escape treatment by acquiring mutations conveying resistance to imatinib mesylate (IM). Following the identification of NKp30-based immunosurveillance of GIST and the off-target effects of IM on NK cell functions, we investigated the predictive value of NKp30 isoforms and NKp30 soluble ligands in blood for the clinical response to IM. The relative expression and the proportions of NKp30 isoforms markedly impacted both event-free and overall survival, in two independent cohorts of metastatic GIST. Phenotypes based on disbalanced NKp30B/NKp30C ratio (Del…

0301 basic medicinemedicine.medical_treatmentImmunologyPDGFRATargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyneoplasmsOriginal ResearchTumor microenvironmentGiSTbusiness.industryCancermedicine.diseasedigestive system diseases3. Good healthImmunosurveillance030104 developmental biologyImatinib mesylateOncology030220 oncology & carcinogenesisImmunologyCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologybusinessTyrosine kinase
researchProduct